Allarity Therapeutics, Inc., a biopharmaceutical company based in Delaware, filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on August 30, 2024, under Form S-3. The filing pertains to the proposed sale of up to 18,529,000 shares of common stock, which may occur from time to time after the registration statement becomes effective. These shares represent approximately 30% of Allarity's outstanding common stock and public float as of August 20, 2024. The shares are issuable upon the conversion of Series A Convertible Redeemable Preferred Stock held by certain selling stockholders identified in the prospectus. The registration statement is part of a shelf registration process, allowing the selling stockholders to sell the shares at their discretion. Allarity Therapeutics will not receive any...Show More

Allarity Therapeutics, Inc., a biopharmaceutical company based in Delaware, filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on August 30, 2024, under Form S-3. The filing pertains to the proposed sale of up to 18,529,000 shares of common stock, which may occur from time to time after the registration statement becomes effective. These shares represent approximately 30% of Allarity's outstanding common stock and public float as of August 20, 2024. The shares are issuable upon the conversion of Series A Convertible Redeemable Preferred Stock held by certain selling stockholders identified in the prospectus. The registration statement is part of a shelf registration process, allowing the selling stockholders to sell the shares at their discretion. Allarity Therapeutics will not receive any proceeds from the resale of the shares, as the sales are solely for the account of the selling stockholders, who will also bear all associated commissions and discounts. The registration of these shares follows the completion of an offering under a Securities Purchase Agreement dated August 19, 2024. The company cautions that the sale or the perception of sale of a large number of shares by the selling stockholders could potentially increase the volatility of the market price of Allarity's common stock or result in a significant decline in its public trading price. Allarity's common stock is traded on The Nasdaq Stock Market LLC under the ticker symbol 'ALLR', and as of August 27, 2024, the closing sale price was $0.1652 per share.